Patents by Inventor Manne KROP

Manne KROP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230160893
    Abstract: The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 25, 2023
    Applicant: B.R.A.H.M.S GMBH
    Inventors: Stefan Ebmeyer, Manne Krop, Jutta Odarjuk
  • Publication number: 20190178897
    Abstract: The present invention relates to the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of organ dysfunction in a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly H2B, H4, H2A and/or H3, in a sample of said subject and wherein said level of at least one histone is indicative of said organ dysfunction. Further, the invention relates to a method that comprises determining a level of proadrenomedullin (proADM), particularly midregional proadrenomedullin (MR-proADM), in a sample of said subject and wherein said level of proADM is indicative of said organ dysfunction. The invention further relates to kits for carrying out the methods of the invention.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 13, 2019
    Inventors: Tim ZIERA, Frauke DREYER, Anne INCAMPS, Manne KROP, Pierre-Emmanuel CHARLES
  • Publication number: 20190178894
    Abstract: The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly histone H2B, H4, H2A and/or H3, in a sample of said subject, and wherein said level of at least one histone is indicative of said adverse event of said subject; and/or determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject. The invention further relates to kits for carrying out the methods of the invention.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 13, 2019
    Inventors: Tim ZIERA, Andre SCHOENICHEN, Anne INCAMPS, Manne KROP, Ingo CURDT, Pierre-Emmanuel CHARLES